80 related articles for article (PubMed ID: 23429593)
1. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Maison-Blanche P; Vermorken JB; Goksel T; Machiels JP; Agarwala S; Rottey S; Daugaard G; Volovat C; Scheulen M; Sengeløv L; Grecea D; Eniu A; Jäger E; Meiri E; Cascinu S; Strumberg D; Demir G; Clemens M; Pinotti G; Nardi M; Guthrie T; Boelle E; Magherini E
J Cardiovasc Pharmacol; 2013 Jun; 61(6):495-504. PubMed ID: 23429593
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
[TBL] [Abstract][Full Text] [Related]
4. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
5. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of vardenafil and sildenafil on cardiac repolarization.
Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
[TBL] [Abstract][Full Text] [Related]
8. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.
Munster PN; Rubin EH; Van Belle S; Friedman E; Patterson JK; Van Dyck K; Li X; Comisar W; Chodakewitz JA; Wagner JA; Iwamoto M
Clin Cancer Res; 2009 Nov; 15(22):7077-84. PubMed ID: 19887475
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
10. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D; Tejpar S; Spano JP; Verslype C; Bloch J; Vandecaveye V; Assadourian S; Soussan-Lazard K; Cartot-Coton S; Van Cutsem E
Eur J Cancer; 2013 Mar; 49(4):790-7. PubMed ID: 23312881
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
12. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Durairaj C; Ruiz-Garcia A; Gauthier ER; Huang X; Lu DR; Hoffman JT; Finn RS; Joy AA; Ettl J; Rugo HS; Zheng J; Wilner KD; Wang DD
Anticancer Drugs; 2018 Mar; 29(3):271-280. PubMed ID: 29360661
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
15. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
[TBL] [Abstract][Full Text] [Related]
16. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C
Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229
[TBL] [Abstract][Full Text] [Related]
17. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
18. Effects of milnacipran on cardiac repolarization in healthy participants.
Periclou A; Palmer RH; Zheng H; Lindamood C
J Clin Pharmacol; 2010 Apr; 50(4):422-33. PubMed ID: 20103694
[TBL] [Abstract][Full Text] [Related]
19. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
Maison-Blanche P; Dakhil S; Baron A; Rottey S; Millard F; Daugaard G; Machiels JP; Conkright W; Sharma S; Soetekouw PM; Yachnin J; Sengeløv L; Van Veldhuizen P; Agarwala SS; Sémiond D; Chadjaa M; Shen L; Wade JL
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1241-52. PubMed ID: 24718982
[TBL] [Abstract][Full Text] [Related]
20. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
